8/31/2023 0 Comments Twist bioscience![]() All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding plans and timing to achieve adjusted EBITDA break-even point for Twist Bioscience's core business and biopharma business, Twist Bioscience’s path to profitability, market opportunities, expansion plans, and Twist Bioscience’s other expectations regarding its future operations plans and financial performance. This press release contains forward-looking statements. Twist Bioscience Legal Notice Regarding Forward-Looking Statements Werner is a Certified Public Accountant and holds a Master’s of accountancy in professional accounting and a Bachelor of Science degree in accounting from Brigham Young University’s Marriott School of Management.įollow us on Twitter | Facebook | LinkedIn | YouTube He held a series of roles of increasing responsibility at Spansion, Inc. He previously served as corporate controller and principal accounting officer at CardioDx and as Corporate Controller at Bloom Energy. Werner served as vice president of finance and corporate controller at Proteus Digital Health. During his time at Invitae, the company grew from $68 million in revenue to $516 million in revenue. He also built out the accounting function to support the growth of the company. Werner was most recently chief accounting officer at Invitae, Inc., where his responsibilities included revenue accounting, corporate accounting, payroll, equity administration, treasury, cost accounting, external reporting, technical accounting and internal audit. I’m looking forward to applying my experience at Twist at this pivotal moment in the company’s evolution, as it transitions toward profitability." "Twist’s unique DNA synthesis platform and ability to write DNA at scale can enable customers across industries to complete groundbreaking research in health and sustainability. ![]() "I have spent the entirety of my career in finance and accounting, with over a decade in biotech, and am proud to join a company with a technology that has so many real world applications," said Mr. "He will be an invaluable addition as Twist continues to gain market share and execute against our plan to achieve adjusted EBITDA breakeven for the core and biopharma businesses at the close of the fiscal fourth quarter of 2024." Leproust, Ph.D., CEO and co-founder of Twist Bioscience. ![]() "Rob has a proven track record of leading corporate and technical accounting, including for global companies as they grow in revenue," said Emily M. SOUTH SAN FRANCISCO, Calif., May 23, 2023-( BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |